Strides Pharma reports Rs. 2,489.7 crore revenue during FY26, 2% YoY growth

Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore

Akums posts strong FY26 performance as EBITDA surges 61.6% in Q4

Senores Pharma doubles profit as sales surge 62%

Global specialty pipeline accelerates growth

CORONA Remedies posts robust FY26 with 17.3% revenue growth, 33.4% PAT surge

The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market

Thyrocare Q4 PAT surges 128% to Rs. 48.7 crore

Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands

Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore

The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year

Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%

Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth

From losses to lift-off: Astec gains ground in Q4 FY26

The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year

Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline